Switch theme
Sign up to access all valuation multiples
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team’s deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
2021
52
LTM Revenue n/a
LTM EBITDA -$89.2M
$407M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ArriVent BioPharma has a last 12-month revenue of n/a and a last 12-month EBITDA of -$89.2M.
In the most recent fiscal year, ArriVent BioPharma achieved revenue of n/a and an EBITDA of -$94.3M.
ArriVent BioPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ArriVent BioPharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$74.6M | -$94.3M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$36.9M | -$69.3M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, ArriVent BioPharma's stock price is $18.
ArriVent BioPharma has current market cap of $625M, and EV of $407M.
See ArriVent BioPharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $407M | $625M | XXX | XXX | XXX | XXX | $-2.66 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, ArriVent BioPharma has market cap of $625M and EV of $407M.
ArriVent BioPharma's trades at n/a LTM EV/Revenue multiple, and -4.6x LTM EBITDA.
Analysts estimate ArriVent BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for ArriVent BioPharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $407M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -4.3x | XXX | XXX | XXX |
| P/E | -7.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -5.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpArriVent BioPharma's NTM/LTM revenue growth is Infinity%
ArriVent BioPharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.8M for the same period.
Over next 12 months, ArriVent BioPharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate ArriVent BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for ArriVent BioPharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ArriVent BioPharma acquired XXX companies to date.
Last acquisition by ArriVent BioPharma was XXXXXXXX, XXXXX XXXXX XXXXXX . ArriVent BioPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was ArriVent BioPharma founded? | ArriVent BioPharma was founded in 2021. |
| Where is ArriVent BioPharma headquartered? | ArriVent BioPharma is headquartered in United States of America. |
| How many employees does ArriVent BioPharma have? | As of today, ArriVent BioPharma has 52 employees. |
| Who is the CEO of ArriVent BioPharma? | ArriVent BioPharma's CEO is Dr. Zhengbin Yao, PhD. |
| Is ArriVent BioPharma publicy listed? | Yes, ArriVent BioPharma is a public company listed on NAS. |
| What is the stock symbol of ArriVent BioPharma? | ArriVent BioPharma trades under AVBP ticker. |
| When did ArriVent BioPharma go public? | ArriVent BioPharma went public in 2024. |
| Who are competitors of ArriVent BioPharma? | Similar companies to ArriVent BioPharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ArriVent BioPharma? | ArriVent BioPharma's current market cap is $625M |
| What is the current EBITDA of ArriVent BioPharma? | ArriVent BioPharma's last 12-month EBITDA is -$89.2M. |
| What is the current EV/EBITDA multiple of ArriVent BioPharma? | Current EBITDA multiple of ArriVent BioPharma is -4.6x. |
| Is ArriVent BioPharma profitable? | Yes, ArriVent BioPharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
